Slide 1: Managing Director's Report 12 Months to 31 July 2018
For personal use only Managing Director’s Report 12 Months to 31 July 2018 21 September 2018
Slide 2: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to adults, infants and children. 1
Slide 3: Full Year Performance Highlights
Full Year Performance Highlights For personal use only Total full year Revenue New products delivering $62.9m up 32% growth in new segments and countries on FY17 $47.9m driven by improved demand Inventory at $19.8m up $1.0m on FY17 full year Net Profit $7.6m up upon forward demand 109% on FY17 $
Slide 4: Full Year 2018 Results
For personal use only Full Year 2018 Results AUD million 4E Reported 4E Reported 32% year on year revenue 31 Jul 2018 31 Jul 2017 growth Revenue $62.9 $47.9 Australia/NZ key growth EBITDA $10.9 $6.1 region NPBT $10.6 $5.0 EBITDA $10.9m (PY $6.1m) Tax ($3.0) ($1.4) Fixed costs managed $8.3m N
Slide 5: Balance Sheet July 2018
Balance Sheet 31 July 2018 For personal use only AUD million Reported Reported Movement 31 Jul 2018 31 July 2017 Cash $7.9 $5.9 +$2.0m Cash balance strong $7.9m Trade Receivables $15.3 $12.1 +$3.2m Trade receivables Inventories $19.8 $18.8 +$1.0m up on FY17 Total Current $43.6 $37.6 +$6.0m refle
Slide 6: Sales by Geography & Product
For personal use only Sales by Geography & Product Sales across key regions Encapsulated Tuna oil have grown during FY18 leads sales revenue with compared to FY17 encapsulated Algal oils and Australia/NZ continue to be other oils represented in major growth region for IF other products for the
Slide 7: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Infant Market formula Development customers Product Development 6
Slide 8: Infant formula maintains growth
For personal use only Growth Platform Market Infant formula Development customer s Infant formula maintains growth Product Development Chinese consumer sentiment for Western brands is driving growth for customers Awarding of CFDA licenses to market and sell product in China has slowed, the CBEC
Slide 9: New products driving future growth
Market Infant formula For personal use only Development customers Growth Platform Product Development New products driving future growth Clover’s Hypoallergenic DHA product continues to win new customers and applications in speciality segments A highly concentrated DHA product which delivers 60%
Slide 10: New markets development
For personal use only Growth Platform Market Development Infant formula customers New markets development Product Development Clover has grown sales in USA, Europe, Asia and ANZ Australia & New Zealand has experienced significant growth servicing the Asian market with several new facilities star
Slide 11: 1HFY19 Outlook & Priorities
1HFY19 Outlook & Priorities For personal use only Growth in European markets driven by the requirement to increase DHA levels in infant formula Clover intends entering into a contract to purchase a share of a spray drying facility in Hamilton, New Zealand Development of new products targeting
Slide 12: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s